Business Wire: “Errant Gene Therapeutics, LLC (“EGT”) Pushing Clinical Trial of Potentially Curative Treatment for Beta-Thalassemia and Eventually Sickle Cell Disease”

TAMPA, Fla.–(BUSINESS WIRE)–The technology, developed by scientists at Memorial Sloan Kettering Cancer Center (“MSKCC”), headed by Dr. Michel Sadelain and Errant Gene Therapeutics, is a one-time treatment that inserts an encoded gene into a patient’s own bone marrow stem cells restoring the production of normal hemoglobin. This technology is known as Thalagen.

View the rest of the article here

View the PDF